

3. (Amended) A method of Claim 1 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.

5. (Amended) A method of Claim 1 [4] wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.

6. (Amended) A method of Claim 5 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

7. (Amended) A method of Claim 3 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s of hTNF $\alpha$  selected from the group consisting of] residues of ~~about 87-108 (SEQ ID NO:1) or [and] about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ .~~ set forth in SEQ ID NO:1 or SEQ ID NO:2.

8. (Amended) A method of Claim 3 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNF $\alpha$  to monoclonal antibody cA2.

9. (Amended) A method of Claim 5 wherein the chimeric antibody is monoclonal antibody cA2.

10. (Amended) A method [for] of treating [or preventing] rheumatoid arthritis in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor alpha antibody to the individual, in therapeutically effective amounts.

11. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered simultaneously.

12. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.

13. (Amended) A method of Claim 10 wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.

14. (Amended) A method of Claim 13 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

15. (Amended) A method of Claim <sup>10</sup>14 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s of hTNF $\alpha$  selected from the group consisting of] residues of about 87-108 (SEQ ID NO:1) or [and] about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ . set forth in SEQ ID NO:1 or SEQ ID NO:2.

16. (Amended) A method of Claim <sup>10</sup>14 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNF $\alpha$  to monoclonal antibody cA2.

17. (Amended) A method of Claim <sup>12</sup>16 wherein the chimeric antibody is monoclonal antibody cA2.

18. (Amended) A method [for] of treating [or preventing] Crohn's disease in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor alpha antibody to the individual, in therapeutically effective amounts.

19. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered simultaneously.

20. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered sequentially.

21. (Amended) A method of Claim 18 wherein the anti-tumor necrosis factor alpha antibody is administered in multiple doses.

22. (Amended) A method of Claim 21 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

<sup>18</sup>  
<sup>22</sup> 22. (Amended) A method of Claim <sup>17</sup>22 wherein the chimeric antibody binds to one or more epitopes included in amino acid[s of hTNF $\alpha$  selected from the group consisting of] residues of about 87-108 (SEQ ID NO:1) or [and] about 59-80 (SEQ ID NO:2) of hTNF $\alpha$ . set forth in SEQ ID NO:1 or SEQ ID NO:2.

<sup>19</sup>  
<sup>24</sup> 24. (Amended) A method of Claim <sup>17</sup>22 wherein the chimeric antibody [binds to the epitope of] competitively inhibits binding of TNF $\alpha$  to monoclonal antibody cA2.

<sup>20</sup>  
<sup>25</sup> 25. (Amended) A method of Claim <sup>17</sup>22 wherein the chimeric antibody is monoclonal antibody cA2.

26. (Amended) A composition comprising methotrexate and an anti-tumor necrosis factor alpha antibody or antigen-binding fragment thereof.

27. (Amended) A composition of Claim 26 wherein the anti-tumor necrosis factor alpha antibody is a chimeric antibody.

<sup>24</sup>  
<sup>28</sup> 28. A composition of Claim <sup>23</sup>27 wherein the chimeric antibody binds to one or more epitopes included in amino acids [of hTNFA selected from the group consisting] of about 87-108 and about 59-80 of hTNF $\alpha$ . residues set forth in SEQ ID NO:1 or SEQ ID NO: 2.